# Reversal of Paraneoplastic Non-Bacterial Thrombotic Endocarditis with Heparin and Targeted Cancer Therapy: A Case Report

**Authors:** Collin Goetze, Nikolaj Frost, Ingo Hilgendorf, Daniel Armando Morris, Matthias Schneider-Reigbert

PMC · DOI: 10.3390/reports9010074 · Reports - Clinical Practice and Surgical Cases · 2026-02-28

## TL;DR

A patient with cancer and heart valve issues improved with heparin and targeted cancer therapy, suggesting better treatment options for similar cases.

## Contribution

This case report demonstrates the reversal of NBTE through heparin and targeted therapy, challenging the use of DOACs in active malignancy.

## Key findings

- Valvular vegetations regressed within two weeks of switching to heparin and starting targeted therapy.
- Complete resolution of vegetations occurred after eight weeks alongside tumor response.
- DOACs may be ineffective in NBTE patients with progressing cancer.

## Abstract

Background and Clinical Significance: Non-bacterial thrombotic endocarditis (NBTE), historically termed marantic endocarditis, is a severe manifestation of cancer-associated hypercoagulability characterized by sterile valvular vegetations and a high risk of systemic embolization. While direct oral anticoagulants (DOACs) have become the standard of care for cancer-associated venous thromboembolism (CAT), their efficacy in preventing high-shear arterial thrombosis in NBTE has been contested. Emerging data suggest that DOACs may fail to halt vegetation growth in active malignancy, necessitating a reversion to heparin-based therapies. Case Presentation: A 47-year-old female with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) presented with progressive dyspnea and digital ischemia despite strict adherence to therapeutic anticoagulation with rivaroxaban for a prior pulmonary embolism. Echocardiography showed large vegetations on all three cusps of the aortic valve, confirming NBTE. Computed tomography revealed extensive tumor progression. The therapeutic strategy involved an immediate switch from rivaroxaban to therapeutic low-molecular-weight heparin (LMWH) and the initiation of dual targeted therapy with selpercatinib and tepotinib. Serial transesophageal echocardiography documented regression within two weeks and eventual complete resolution of the valvular vegetations after eight weeks, occurring in tandem with a rapid radiological response of the tumor. Conclusions: Upon diagnosis of NBTE, a rapid oncologic work-up is warranted, as ongoing tumor progression is highly likely. This case questions the appropriateness of direct oral anticoagulants in patients with NBTE and active, progressive malignancy.

## Linked entities

- **Chemicals:** rivaroxaban (PubChem CID 6433119), selpercatinib (PubChem CID 134436906), tepotinib (PubChem CID 25171648)
- **Diseases:** non-bacterial thrombotic endocarditis (MONDO:0000610), non-small cell lung cancer (MONDO:0005233), pulmonary embolism (MONDO:0005279)

## Full-text entities

- **Genes:** SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, TFPI (tissue factor pathway inhibitor) [NCBI Gene 7035] {aka EPI, LACI, TFI, TFPI1}, mucin [NCBI Gene 100508689], RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, KIF5B (kinesin family member 5B) [NCBI Gene 3799] {aka HEL-S-61, KINH, KNS, KNS1, UKHC}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, F10 (coagulation factor X) [NCBI Gene 2159] {aka FX, FXA}
- **Diseases:** lung adenocarcinoma (MESH:D000077192), paraneoplastic (MESH:D010257), hepatic lesion (MESH:D056486), pulmonary embolism (MESH:D011655), hypoxemia (MESH:D000860), Cancer (MESH:D009369), aortic stenosis (MESH:D001024), hypercoagulability (MESH:D019851), thromboembolic conditions (MESH:D013923), NBTE (MESH:D059905), pleural effusion (MESH:D010996), Endocarditis (MESH:D004696), embolic (MESH:D004617), peripheral arterial occlusion (MESH:C564658), valvular lesions (MESH:D006349), Thrombotic (MESH:D013927), inflammation (MESH:D007249), adenocarcinomas (MESH:D000230), injury to (MESH:D014947), microbial infection (MESH:D015163), dizziness (MESH:D004244), ischemic stroke (MESH:D002544), infection (MESH:D007239), venous disease (MESH:D004194), malignant pleural effusion (MESH:D016066), hepatic and pulmonary metastases (MESH:D009362), cardiovascular disease (MESH:D002318), painful (MESH:D010146), NSCLC (MESH:D002289), stage IVB (MESH:D009085), aortic regurgitation (MESH:D001022), CAT (MESH:D054556), deep vein thrombosis (MESH:D020246), digital ischemia (MESH:D007511), tachycardia (MESH:D013610), dyspnea (MESH:D004417), oncologic (MESH:D000072716)
- **Chemicals:** vancomycin (MESH:D014640), LMWH (MESH:D006495), nadroparin (MESH:D017762), apixaban (MESH:C522181), Rivaroxaban (MESH:D000069552), selpercatinib (MESH:C000656166), pemetrexed (MESH:D000068437), DOAC (-), oxygen (MESH:D010100), cefotaxime (MESH:D002439), Heparin (MESH:D006493), tepotinib (MESH:C000707607), cisplatin (MESH:D002945)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13030534/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13030534/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC13030534/full.md

---
Source: https://tomesphere.com/paper/PMC13030534